286 related articles for article (PubMed ID: 29257923)
1. FGFR1 signaling potentiates tumor growth and predicts poor prognosis in esophageal squamous cell carcinoma patients.
Chen B; Liu S; Gan L; Wang J; Hu B; Xu H; Tong R; Yang H; Cristina I; Xue J; Hu X; Lu Y
Cancer Biol Ther; 2018 Jan; 19(1):76-86. PubMed ID: 29257923
[TBL] [Abstract][Full Text] [Related]
2. Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma.
Lam SK; Leung LL; Li YY; Zheng CY; Ho JC
Lung Cancer; 2016 Nov; 101():111-119. PubMed ID: 27794399
[TBL] [Abstract][Full Text] [Related]
3. RNF113A promotes the proliferation, migration and invasion, and is associated with a poor prognosis of esophageal squamous cell carcinoma.
Wang L; Hou Z; Hasim A; Abuduerheman A; Zhang H; Niyaz M; Awut I; Upur H; Sheyhidin I
Int J Oncol; 2018 Mar; 52(3):861-871. PubMed ID: 29393393
[TBL] [Abstract][Full Text] [Related]
4. Prognostic implications of
Kwon D; Yun JY; Keam B; Kim YT; Jeon YK
World J Gastroenterol; 2016 Nov; 22(44):9803-9812. PubMed ID: 27956804
[TBL] [Abstract][Full Text] [Related]
5. Increased Numb protein expression predicts poor clinical outcomes in esophageal squamous cell carcinoma patients.
Liu Z; Luo C; Yang W; Wang K; Hu C; Zou J; Zhu H; Fu L; Nie J; Cheng C
Cancer Biol Ther; 2018 Jan; 19(1):34-41. PubMed ID: 28095111
[TBL] [Abstract][Full Text] [Related]
6. MTA1 promotes tumorigenesis and development of esophageal squamous cell carcinoma via activating the MEK/ERK/p90RSK signaling pathway.
Nan P; Wang T; Li C; Li H; Wang J; Zhang J; Dou N; Zhan Q; Ma F; Wang H; Qian H
Carcinogenesis; 2020 Sep; 41(9):1263-1272. PubMed ID: 31783401
[TBL] [Abstract][Full Text] [Related]
7. HERG1 promotes esophageal squamous cell carcinoma growth and metastasis through TXNDC5 by activating the PI3K/AKT pathway.
Wang H; Yang X; Guo Y; Shui L; Li S; Bai Y; Liu Y; Zeng M; Xia J
J Exp Clin Cancer Res; 2019 Jul; 38(1):324. PubMed ID: 31331361
[TBL] [Abstract][Full Text] [Related]
8. TEX9 and eIF3b functionally synergize to promote the progression of esophageal squamous cell carcinoma.
Xu F; Zhang S; Liu Z; Gu J; Li Y; Wang L; Mao W; Zhu Q; Shou H; Ge D; Lu C
BMC Cancer; 2019 Sep; 19(1):875. PubMed ID: 31481019
[TBL] [Abstract][Full Text] [Related]
9. Catalytically inactive receptor tyrosine kinase PTK7 activates FGFR1 independent of FGF.
Shin WS; Lee HW; Lee ST
FASEB J; 2019 Nov; 33(11):12960-12971. PubMed ID: 31490704
[TBL] [Abstract][Full Text] [Related]
10. Suppressor of cytokine signaling-1 gene therapy induces potent antitumor effect in patient-derived esophageal squamous cell carcinoma xenograft mice.
Sugase T; Takahashi T; Serada S; Nakatsuka R; Fujimoto M; Ohkawara T; Hara H; Nishigaki T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Kishimoto T; Mori M; Doki Y; Naka T
Int J Cancer; 2017 Jun; 140(11):2608-2621. PubMed ID: 28233302
[TBL] [Abstract][Full Text] [Related]
11. Eukaryotic translation initiation factor 3B accelerates the progression of esophageal squamous cell carcinoma by activating β-catenin signaling pathway.
Xu F; Xu CZ; Gu J; Liu X; Liu R; Huang E; Yuan Y; Zhao G; Jiang J; Xu C; Chu Y; Lu C; Ge D
Oncotarget; 2016 Jul; 7(28):43401-43411. PubMed ID: 27270324
[TBL] [Abstract][Full Text] [Related]
12. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
[TBL] [Abstract][Full Text] [Related]
13. [The inhibition effects of apatinib on cell proliferation, migration and apoptosis in esophageal carcinoma via Ras/Raf/MEK/ERK and JAK2/STAT3 pathways].
Feng Y; Zhou MY; Sun F; Kong Z; Wang J; Sun ZQ; Hu LJ; Wang JL; Hua Q; Yu JP
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):263-275. PubMed ID: 31014051
[No Abstract] [Full Text] [Related]
14. Pristimerin targeting NF-κB pathway inhibits proliferation, migration, and invasion in esophageal squamous cell carcinoma cells.
Tu Y; Tan F; Zhou J; Pan J
Cell Biochem Funct; 2018 Jun; 36(4):228-240. PubMed ID: 29781107
[TBL] [Abstract][Full Text] [Related]
15. LncRNA-TUSC7/miR-224 affected chemotherapy resistance of esophageal squamous cell carcinoma by competitively regulating DESC1.
Chang ZW; Jia YX; Zhang WJ; Song LJ; Gao M; Li MJ; Zhao RH; Li J; Zhong YL; Sun QZ; Qin YR
J Exp Clin Cancer Res; 2018 Mar; 37(1):56. PubMed ID: 29530057
[TBL] [Abstract][Full Text] [Related]
16. FGFR inhibitor AZD4547 can enhance sensitivity of esophageal squamous cell carcinoma cells with epithelial‑mesenchymal transition to gefitinib.
Luo H; Quan J; Xiao H; Luo J; Zhang Q; Pi G; Ye Y; He R; Liu Y; Su X; Zhao L; Wang G
Oncol Rep; 2018 May; 39(5):2270-2278. PubMed ID: 29517107
[TBL] [Abstract][Full Text] [Related]
17. High MLL2 expression predicts poor prognosis and promotes tumor progression by inducing EMT in esophageal squamous cell carcinoma.
Abudureheman A; Ainiwaer J; Hou Z; Niyaz M; Turghun A; Hasim A; Zhang H; Lu X; Sheyhidin I
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1025-1035. PubMed ID: 29532228
[TBL] [Abstract][Full Text] [Related]
18. RACK1 predicts poor prognosis and regulates progression of esophageal squamous cell carcinoma through its epithelial-mesenchymal transition.
Wang N; Liu F; Cao F; Jia Y; Wang J; Ma W; Tan B; Wang K; Song Q; Cheng Y
Cancer Biol Ther; 2015; 16(4):528-40. PubMed ID: 25719728
[TBL] [Abstract][Full Text] [Related]
19. Low expression of PRDM5 predicts poor prognosis of esophageal squamous cell carcinoma.
Guo J; Yang Q; Wei S; Shao J; Zhao T; Guo L; Liu J; Chen J; Wang G
BMC Cancer; 2022 Jul; 22(1):745. PubMed ID: 35799142
[TBL] [Abstract][Full Text] [Related]
20. FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers.
Göke F; Franzen A; Hinz TK; Marek LA; Yoon P; Sharma R; Bode M; von Maessenhausen A; Lankat-Buttgereit B; Göke A; Golletz C; Kirsten R; Boehm D; Vogel W; Kleczko EK; Eagles JR; Hirsch FR; Van Bremen T; Bootz F; Schroeck A; Kim J; Tan AC; Jimeno A; Heasley LE; Perner S
Clin Cancer Res; 2015 Oct; 21(19):4356-64. PubMed ID: 26015511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
